<DOC>
	<DOCNO>NCT00022386</DOCNO>
	<brief_summary>RATIONALE : Epoetin alfa may stimulate red blood cell production treat patient anemia follow chemotherapy . PURPOSE : Phase IV trial study effectiveness epoetin alfa treat chemotherapy-related anemia woman stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Epoetin Alfa Treating Chemotherapy-Related Anemia Women With Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effectiveness safety epoetin alfa patient receive adjuvant chemotherapy stage I , II , III breast cancer . II . Determine clinical outcome patient receive drug . OUTLINE : This multicenter study . Patients receive epoetin alfa subcutaneously weekly 24 week absence unacceptable toxicity . Quality life assess baseline , week 13 , study completion . PROJECTED ACCRUAL : A maximum 2,500 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage I , II , III breast cancer Planned adjuvant anthracyclinebased chemotherapy without taxane 36 month Hemoglobin 1014 g/dL ( independent transfusion ) No anemia due factor cancer/chemotherapy ( i.e. , iron , cyanocobalamin , folate deficiency ; hemolysis ; gastrointestinal bleeding ; myelodysplastic syndrome ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 9 month Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Cardiovascular : No uncontrolled severe cardiovascular disease No myocardial infarction within past 6 month No uncontrolled hypertension No congestive heart failure Other : No hypersensitivity mammalian cellderived product No hypersensitivity human albumin Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior epoetin alfa investigational form erythropoietin ( e.g. , geneactivated erythropoietin novel erythropoiesis stimulate protein ) No transfusion within past 30 day No concurrent epoetin alfa Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent investigational drug No concurrent treatment anemia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>anemia</keyword>
	<keyword>fatigue</keyword>
</DOC>